CytoDyn Inc. (CYDY) Financial Statements (2026 and earlier)

Company Profile

Business Address 1111 MAIN STREET, SUITE 660
VANCOUVER, WA 98660
State of Incorp. DE
Fiscal Year End May 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

2/28/2026
MRQ
11/30/2025
MRQ
5/31/2025
5/31/2024
5/31/2023
5/31/2022
5/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,98211,9033,1102,5414,23133,943
Cash and cash equivalent4,98211,9033,1102,5414,23133,943
Restricted cash and investments   6,7046,507  
Inventory, net of allowances, customer advances and progress billings      93,479
Inventory      93,479
Prepaid expense5602524631,1675,198616
Other undisclosed current assets3,2975,7235385901,0861,543
Total current assets:8,83917,87810,81510,80510,515129,581
Noncurrent Assets
Inventory, Noncurrent     17,929 
Operating lease, right-of-use asset     536712
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization     73134
Intangible asset, including goodwill, after accumulated amortization     1321,653
Intangible asset, excluding goodwill, after accumulated amortization     1321,653
Other noncurrent assets96169321487  
Total noncurrent assets:9616932148718,6702,499
TOTAL ASSETS:8,93518,04711,13611,29229,185132,080
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities38,49341,39051,78778,96679,42974,556
Interest and dividends payable✕✕✕✕✕9,9514,654
Employee-related liabilities✕✕✕✕✕1,5044,005
Accounts payable14,24514,69229,56162,72567,97465,897
Accrued liabilities24,24826,69822,22616,241  
Debt 27,20027,20029,79334,41736,24162,747
Derivative instruments and hedges, liabilities    79  
Estimated litigation liability16,5875071682,00611,008
Other liabilities 614525 1,6244,060
Other undisclosed current liabilities2,8261,7332,5706,1663,861175
Total current liabilities:85,11270,51884,182119,796123,161152,546
Noncurrent Liabilities
Long-term debt and lease obligation    422552
Long-term debt, excluding current maturities      
Liabilities, other than long-term debt43,57143,57143,712283  
Other liabilities43,57143,57143,571   
Operating lease, liability   141283422552
Other undisclosed noncurrent liabilities   714(422)(552)
Total noncurrent liabilities:43,57143,57143,712997422552
Total liabilities:128,683114,089127,894120,793123,583153,098
Equity
Equity, attributable to parent(119,748)(96,042)(116,758)(109,501)(94,398)(21,018)
Common stock1,2661,2491,059919720626
Additional paid in capital794,919790,495773,714731,270671,013489,650
Accumulated deficit(915,933)(887,786)(891,531)(841,690)(766,131)(511,294)
Total equity:(119,748)(96,042)(116,758)(109,501)(94,398)(21,018)
TOTAL LIABILITIES AND EQUITY:8,93518,04711,13611,29229,185132,080

Income Statement (P&L) ($ in thousands)

2/28/2026
TTM
11/30/2025
TTM
5/31/2025
5/31/2024
5/31/2023
5/31/2022
5/31/2021
Revenues     266 
Cost of revenue(9,026) (29)(20,633)(53)(1,797)
Cost of product and service sold(4)  (20,633)(73,490)(1,797)
Gross profit:(9,026) (29)(20,633)213(1,797)
Operating expenses(23,461)(7,260)(18,029)(19,943)(72,127)(102,799)
Other undisclosed operating income (loss)(3,215)17,773  (73,490) 
Operating income (loss):(35,702)9,661(18,058)(40,576)(145,404)(104,596)
Nonoperating income
(Investment Income, Nonoperating)
448565   2
Interest and debt expense 327407(31,783)(39,248)(65,416)(31,474)
Income (loss) from continuing operations before equity method investments, income taxes:(34,927)10,633(49,841)(79,824)(210,820)(136,068)
Other undisclosed loss from continuing operations before income taxes(3,934)(6,888)   (18,606)
Income (loss) from continuing operations:(38,861)3,745(49,841)(79,824)(210,820)(154,674)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(210,820)(154,674)
Net income (loss) attributable to parent:(38,861)3,745(49,841)(79,824)(210,820)(154,674)
Preferred stock dividends and other adjustments(1,484)(1,483)(1,483)(1,495)1,628 
Other undisclosed net loss available to common stockholders, basic(1)(1) (5,417)(3,256) 
Net income (loss) available to common stockholders, diluted:(40,346)2,261(51,324)(86,736)(212,448)(154,674)

Comprehensive Income ($ in thousands)

2/28/2026
TTM
11/30/2025
TTM
5/31/2025
5/31/2024
5/31/2023
5/31/2022
5/31/2021
Net income (loss):(38,861)3,745(49,841)(79,824)(210,820)(154,674)
Comprehensive income (loss), net of tax, attributable to parent:(38,861)3,745(49,841)(79,824)(210,820)(154,674)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: